Immunotherapy for opportunistic infections: Current status and future perspectives

References

• Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, Martin PJ, Sandmaier BM, Marr KA, Appelbaum FR, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363:2091-101; PMID:21105791; http://dx.doi.org/10.1056/NEJMoa1004383
   PubMed Web of Science ®Google Scholar
• Afessa B, Peters SG. Major complications following hematopoietic stem cell transplantation. Semin Respir Crit Care Med 2006; 27:297-309; PMID:16791762; http://dx.doi.org/10.1055/s-2006-945530
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P, et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 2005; 36:757-69; PMID:16151426; http://dx.doi.org/10.1038/sj.bmt.1705140
   PubMed Web of Science ®Google Scholar
• Styczynski J, Czyzewski K, Wysocki M, Gryniewicz-Kwiatkowska O, Kolodziejczyk-Gietka A, Salamonowicz M, Hutnik L, Zajac-Spychala O, Zaucha-Prazmo A, Chelmecka-Wiktorczyk L, et al. Increased risk of infections and infection-related mortality in children undergoing haematopoietic stem cell transplantation compared to conventional anticancer therapy: a multicentre nationwide study. Clin Microbiol Infect 2016; 22:179 e1-e10; PMID:26493843; http://dx.doi.org/10.1016/j.cmi.2015.10.017
   PubMedGoogle Scholar
• Crocchiolo R, Bramanti S, Vai A, Sarina B, Mineri R, Casari E, Tordato F, Mauro E, Timofeeva I, Lugli E, et al. Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-vs.-host disease prophylaxis. Transpl Infect Dis 2015; 17:242-9; PMID:25648539; http://dx.doi.org/10.1111/tid.12365
   PubMed Web of Science ®Google Scholar
• Park M, Lee YH, Lee SH, Yoo KH, Sung KW, Koo HH, Lee JW, Kang HJ, Park KD, Shin HY, et al. Cytomegalovirus infection in seropositive unrelated cord blood recipients: a study of 349 Korean patients. Ann Hematol 2015; 94:481-9; PMID:25417830; http://dx.doi.org/10.1007/s00277-014-2222-x
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie E. How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach. Blood 2014; 124:3858-69; PMID:25339358; http://dx.doi.org/10.1182/blood-2014-04-516211
   PubMed Web of Science ®Google Scholar
• Lindemans CA, Leen AM, Boelens JJ. How I treat adenovirus in hematopoietic stem cell transplant recipients. Blood 2010; 116:5476-85; PMID:20837781; http://dx.doi.org/10.1182/blood-2010-04-259291
   PubMed Web of Science ®Google Scholar
• Boeckh M, Murphy WJ, Peggs KS. Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies. Biol Blood Marrow Transplant 2015; 21:24-9; PMID:25452035; http://dx.doi.org/10.1016/j.bbmt.2014.11.002
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50:1091-100; PMID:20218877; http://dx.doi.org/10.1086/651263
   PubMed Web of Science ®Google Scholar
• Corzo-Leon DE, Satlin MJ, Soave R, Shore TB, Schuetz AN, Jacobs SE, Walsh TJ. Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a single-centre study with focus on emerging pathogens. Mycoses 2015; 58:325-36; PMID:25808822; http://dx.doi.org/10.1111/myc.12318
   PubMed Web of Science ®Google Scholar
• Marr KA. Delayed opportunistic infections in hematopoietic stem cell transplantation patients: a surmountable challenge. Hematology Am Soc Hematol Edu Program 2012; 2012:265-70; PMID:23233590
   PubMedGoogle Scholar
• Boeckh M, Nichols WG, Chemaly RF, Papanicolaou GA, Wingard JR, Xie H, Syrjala KL, Flowers ME, Stevens-Ayers T, Jerome KR, et al. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Annals Intern Med 2015; 162:1-10; http://dx.doi.org/10.7326/M13-2729
   PubMed Web of Science ®Google Scholar
• Seyedmousavi S, Mouton JW, Melchers WJ, Bruggemann RJ, Verweij PE. The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside. Drug Resist Updat 2014; 17:37-50; PMID:25066814; http://dx.doi.org/10.1016/j.drup.2014.06.001
   PubMed Web of Science ®Google Scholar
• van der Linden JW, Camps SM, Kampinga GA, Arends JP, Debets-Ossenkopp YJ, Haas PJ, Rijnders BJ, Kuijper EJ, van Tiel FH, Varga J, et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis 2013; 57:513-20; PMID:23667263; http://dx.doi.org/10.1093/cid/cit320
   PubMed Web of Science ®Google Scholar
• Steinmann J, Hamprecht A, Vehreschild MJ, Cornely OA, Buchheidt D, Spiess B, Koldehoff M, Buer J, Meis JF, Rath PM. Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. J Antimicrob Chemother 2015; 70:1522-6; PMID:25630644; http://dx.doi.org/10.1093/jac/dku566
   PubMed Web of Science ®Google Scholar
• Hadrich I, Makni F, Neji S, Abbes S, Cheikhrouhou F, Trabelsi H, Sellami H, Ayadi A. Invasive aspergillosis: resistance to antifungal drugs. Mycopathologia 2012; 174:131-41; PMID:22327841; http://dx.doi.org/10.1007/s11046-012-9526-y
   PubMed Web of Science ®Google Scholar
• Komatsu TE, Pikis A, Naeger LK, Harrington PR. Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative resistance pathways. Antiviral Res 2014; 101:12-25; PMID:24184129; http://dx.doi.org/10.1016/j.antiviral.2013.10.011
   PubMed Web of Science ®Google Scholar
• Campos AB, Ribeiro J, Boutolleau D, Sousa H. Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art. Rev Med Virol 2016; 26(3):161-82; PMID:26990717
   PubMed Web of Science ®Google Scholar
• Shmueli E, Or R, Shapira MY, Resnick IB, Caplan O, Bdolah-Abram T, Wolf DG. High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation. J Infect Dis 2014; 209:557-61; PMID:23983215; http://dx.doi.org/10.1093/infdis/jit475
   PubMed Web of Science ®Google Scholar
• Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, Stevens-Ayers T, Flowers ME, Cunningham T, Corey L. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003; 101:407-14; PMID:12393659; http://dx.doi.org/10.1182/blood-2002-03-0993
   PubMed Web of Science ®Google Scholar
• Heemskerk B, Lankester AC, van Vreeswijk T, Beersma MF, Claas EC, Veltrop-Duits LA, Kroes AC, Vossen JM, Schilham MW, van Tol MJ. Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients. J Infect Dis 2005; 191:520-30; PMID:15655775; http://dx.doi.org/10.1086/427513
   PubMed Web of Science ®Google Scholar
• Tormo N, Solano C, Benet I, Clari MA, Nieto J, de la Camara R, López J, López-Aldeguer N, Hernández-Boluda JC, Remigia MJ, et al. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2010; 45:543-9; PMID:19617905; http://dx.doi.org/10.1038/bmt.2009.172
   PubMed Web of Science ®Google Scholar
• Tormo N, Solano C, Benet I, Nieto J, de la Camara R, Lopez J, Garcia-Noblejas A, Muñoz-Cobo B, Costa E, Clari MA, et al. Reconstitution of CMV pp65 and IE-1-specific IFN-gamma CD8(+) and CD4(+) T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT. Bone Marrow Transplant 2011; 46:1437-43; PMID:21243030; http://dx.doi.org/10.1038/bmt.2010.330
   PubMed Web of Science ®Google Scholar
• Gratama JW, Boeckh M, Nakamura R, Cornelissen JJ, Brooimans RA, Zaia JA, Forman SJ, Gaal K, Bray KR, Gasior GH, et al. Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood 2010; 116:1655-62; PMID:20508161; http://dx.doi.org/10.1182/blood-2010-03-273508
   PubMed Web of Science ®Google Scholar
• Gratama JW, Brooimans RA, van der Holt B, Sintnicolaas K, van Doornum G, Niesters HG, Löwenberg B, Cornelissen JJ. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations. Cytometry B Clin Cytom 2008; 74:211-20; PMID:18454493; http://dx.doi.org/10.1002/cyto.b.20420
   PubMed Web of Science ®Google Scholar
• Borchers S, Luther S, Lips U, Hahn N, Kontsendorn J, Stadler M, Buchholz S, Diedrich H, Eder M, Koehl U, et al. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2011; 13:222-36; PMID:21585633; http://dx.doi.org/10.1111/j.1399-3062.2011.00626.x
   PubMed Web of Science ®Google Scholar
• Gratama JW, van Esser JW, Lamers CH, Tournay C, Lowenberg B, Bolhuis RL, Cornelissen JJ. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001; 98:1358-64; PMID:11520783; http://dx.doi.org/10.1182/blood.V98.5.1358
   PubMed Web of Science ®Google Scholar
• Ganepola S, Gentilini C, Hilbers U, Lange T, Rieger K, Hofmann J, Maier M, Liebert UG, Niederwieser D, Engelmann E, et al. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39:293-9; PMID:17262060; http://dx.doi.org/10.1038/sj.bmt.1705585
   PubMed Web of Science ®Google Scholar
• Heslop HE. How I treat EBV lymphoproliferation. Blood 2009; 114:4002-8; PMID:19724053; http://dx.doi.org/10.1182/blood-2009-07-143545
   PubMed Web of Science ®Google Scholar
• Romani L. Immunity to fungal infections. Nat Rev Immunol 2011; 11:275-88; PMID:21394104; http://dx.doi.org/10.1038/nri2939
   PubMed Web of Science ®Google Scholar
• Fuji S, Kapp M, Einsele H. Monitoring of pathogen-specific T-cell immune reconstitution after allogeneic hematopoietic stem cell transplantation. Front Immunol 2013; 4:276; PMID:24062744
   PubMed Web of Science ®Google Scholar
• Fuji S, Kapp M, Grigoleit GU, Einsele H. Adoptive immunotherapy with virus-specific T cells. Best Pract Res Clin Haematol 2011; 24:413-9; PMID:21925094; http://dx.doi.org/10.1016/j.beha.2011.06.003
   PubMed Web of Science ®Google Scholar
• Einsele H, Hamprecht K. Immunotherapy of cytomegalovirus infection after stem-cell transplantation: a new option? Lancet 2003; 362:1343-4; PMID:14585632; http://dx.doi.org/10.1016/S0140-6736(03)14673-9
   PubMed Web of Science ®Google Scholar
• Einsele H, Mielke S, Grigoleit GU. Diagnosis and treatment of cytomegalovirus 2013. Curr Opin Hematol 2014; 21:470-5; PMID:25295744; http://dx.doi.org/10.1097/MOH.0000000000000090
   PubMed Web of Science ®Google Scholar
• Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J, Grigoleit U, Moris A, Rammensee HG, Kanz L, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99:3916-22; PMID:12010789; http://dx.doi.org/10.1182/blood.V99.11.3916
   PubMed Web of Science ®Google Scholar
• Hiwarkar P, Gaspar HB, Gilmour K, Jagani M, Chiesa R, Bennett-Rees N, Breuer J, Rao K, Cale C, Goulden N, et al. Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients. Bone Marrow Transplant 2013; 48:803-8; PMID:23178547; http://dx.doi.org/10.1038/bmt.2012.221
   PubMed Web of Science ®Google Scholar
• Kampmann B, Cubitt D, Walls T, Naik P, Depala M, Samarasinghe S, Robson D, Hassan A, Rao K, Gaspar H, et al. Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation. Br J Haematol 2005; 130:595-603; PMID:16098075; http://dx.doi.org/10.1111/j.1365-2141.2005.05649.x
   PubMed Web of Science ®Google Scholar
• Hislop AD, Taylor GS. T-Cell Responses to EBV. Curr Top Microbiol Immunol 2015; 391:325-53; PMID:26428380
   PubMed Web of Science ®Google Scholar
• Knabel M, Franz TJ, Schiemann M, Wulf A, Villmow B, Schmidt B, Bernhard H, Wagner H, Busch DH. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med 2002; 8:631-7; PMID:12042816; http://dx.doi.org/10.1038/nm0602-631
   PubMed Web of Science ®Google Scholar
• Neudorfer J, Schmidt B, Huster KM, Anderl F, Schiemann M, Holzapfel G, Schmidt T, Germeroth L, Wagner H, Peschel C, et al. Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. J Immunol Methods 2007; 320:119-31; PMID:17306825; http://dx.doi.org/10.1016/j.jim.2007.01.001
   PubMed Web of Science ®Google Scholar
• Ciaurriz M, Beloki L, Bandres E, Mansilla C, Zabalza A, Perez-Valderrama E, Lachén M, Ibáñez B, Olavarría E, Ramírez N. Streptamer technology allows accurate and specific detection of CMV-specific HLA-A*02 CD8 T cells by flow cytometry. Cytometry B Clin Cytom 2016; [epub ahead of print] PMID:26918565 http://dx.doi.org/10.1002/cyto.b.21367
   PubMedGoogle Scholar
• Wang XC, Pang H, Xu X, Schmitt A, Freund M, Schmitt M, Chen BA. Streptamer versus tetramer-based selection of functional cytomegalovirus-specific T cells. J Formos Med Assoc 2013; 112:338-45; PMID:23787011; http://dx.doi.org/10.1016/j.jfma.2012.02.020
   PubMed Web of Science ®Google Scholar
• Odendahl M, Grigoleit GU, Bonig H, Neuenhahn M, Albrecht J, Anderl F, Germeroth L, Schmitz M, Bornhäuser M, Einsele H, et al. Clinical-scale isolation of “minimally manipulated” cytomegalovirus-specific donor lymphocytes for the treatment of refractory cytomegalovirus disease. Cytotherapy 2014; 16:1245-56; PMID:25108651; http://dx.doi.org/10.1016/j.jcyt.2014.05.023
   PubMed Web of Science ®Google Scholar
• Schmitt A, Tonn T, Busch DH, Grigoleit GU, Einsele H, Odendahl M, Germeroth L, Ringhoffer M, Ringhoffer S, Wiesneth M, et al. Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 2011; 51:591-9; PMID:21133926; http://dx.doi.org/10.1111/j.1537-2995.2010.02940.x
   PubMed Web of Science ®Google Scholar
• Freimuller C, Stemberger J, Artwohl M, Germeroth L, Witt V, Fischer G, Tischer S, Eiz-Vesper B, Knippertz I, Dörrie J, et al. Selection of adenovirus-specific and Epstein-Barr virus-specific T cells with major histocompatibility class I streptamers under Good Manufacturing Practice (GMP)-compliant conditions. Cytotherapy 2015; 17:989-1007; PMID:25866178; http://dx.doi.org/10.1016/j.jcyt.2015.03.613
   PubMed Web of Science ®Google Scholar
• Feucht J, Joachim L, Lang P, Feuchtinger T. Adoptive T-cell transfer for refractory viral infections with cytomegalovirus, Epstein-Barr virus or adenovirus after allogeneic stem cell transplantation. Klinische Padiatrie 2013; 225:164-9; PMID:23700092; http://dx.doi.org/10.1055/s-0033-1333749
   PubMed Web of Science ®Google Scholar
• Feuchtinger T, Lang P, Hamprecht K, Schumm M, Greil J, Jahn G, Niethammer D, Einsele H. Isolation and expansion of human adenovirus-specific CD4+ and CD8+ T cells according to IFN-gamma secretion for adjuvant immunotherapy. Exp Hematol 2004; 32:282-9; PMID:15003314; http://dx.doi.org/10.1016/j.exphem.2003.12.009
   PubMed Web of Science ®Google Scholar
• Peggs KS, Thomson K, Samuel E, Dyer G, Armoogum J, Chakraverty R, Pang K, Mackinnon S, Lowdell MW. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis 2011; 52:49-57; PMID:21148519; http://dx.doi.org/10.1093/cid/ciq042
   PubMed Web of Science ®Google Scholar
• Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR, Weissinger EM, Mohty M, Or R, Maschan M, Schumm M, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010; 116:4360-7; PMID:20625005; http://dx.doi.org/10.1182/blood-2010-01-262089
   PubMed Web of Science ®Google Scholar
• Feucht J, Opherk K, Lang P, Kayser S, Hartl L, Bethge W, Matthes-Martin S, Bader P, Albert MH, Maecker-Kolhoff B, et al. Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. Blood 2015; 125:1986-94; PMID:25617426; http://dx.doi.org/10.1182/blood-2014-06-573725
   PubMed Web of Science ®Google Scholar
• Feuchtinger T, Matthes-Martin S, Richard C, Lion T, Fuhrer M, Hamprecht K, Handgretinger R, Peters C, Schuster FR, Beck R, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006; 134:64-76; PMID:16803570; http://dx.doi.org/10.1111/j.1365-2141.2006.06108.x
   PubMed Web of Science ®Google Scholar
• Feuchtinger T, Richard C, Joachim S, Scheible MH, Schumm M, Hamprecht K, Martin D, Jahn G, Handgretinger R, Lang P. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. J Immunother 2008; 31:199-206; PMID:18481389; http://dx.doi.org/10.1097/CJI.0b013e31815ef862
   PubMed Web of Science ®Google Scholar
• Qasim W, Gilmour K, Zhan H, Derniame S, McNicol AM, Ip W, Hiwarkar P, Veys P, Gaspar HB. Interferon-gamma capture T cell therapy for persistent Adenoviraemia following allogeneic haematopoietic stem cell transplantation. Br J Haematol 2013; 161:449-52; PMID:23432400; http://dx.doi.org/10.1111/bjh.12251
   PubMed Web of Science ®Google Scholar
• Moosmann A, Bigalke I, Tischer J, Schirrmann L, Kasten J, Tippmer S, Leeping M, Prevalsek D, Jaeger G, Ledderose G, et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 2010; 115:2960-70; PMID:20103780; http://dx.doi.org/10.1182/blood-2009-08-236356
   PubMed Web of Science ®Google Scholar
• Icheva V, Kayser S, Wolff D, Tuve S, Kyzirakos C, Bethge W, Greil J, Albert MH, Schwinger W, Nathrath M, et al. Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol 2013; 31:39-48; PMID:23169501; http://dx.doi.org/10.1200/JCO.2011.39.8495
   PubMed Web of Science ®Google Scholar
• Qian C, Wang Y, Cai H, Laroye C, De Carvalho Bittencourt M, Clement L, Stoltz JF, Decot V, Reppel L, Bensoussan D. Adenovirus-specific T-cell Subsets in Human Peripheral Blood and After IFN-gamma Immunomagnetic Selection. J Immunother 2016; 39:27-35; PMID:26641259
   PubMed Web of Science ®Google Scholar
• Papadopoulou A, Gerdemann U, Katari UL, Tzannou I, Liu H, Martinez C, Leung K, Carrum G, Gee AP, Vera JF, et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med 2014; 6:242ra83; PMID:24964991; http://dx.doi.org/10.1126/scitranslmed.3008825
   PubMed Web of Science ®Google Scholar
• Geyeregger R, Freimuller C, Stemberger J, Artwohl M, Witt V, Lion T, Fischer G, Lawitschka A, Ritter J, Hummel M, et al. First-in-man clinical results with good manufacturing practice (GMP)-compliant polypeptide-expanded adenovirus-specific T cells after haploidentical hematopoietic stem cell transplantation. J Immunother 2014; 37:245-9; PMID:24714358
   PubMed Web of Science ®Google Scholar
• Vera JF, Brenner LJ, Gerdemann U, Ngo MC, Sili U, Liu H, Wilson J, Dotti G, Heslop HE, Leen AM, et al. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother 2010; 33:305-15; PMID:20445351; http://dx.doi.org/10.1097/CJI.0b013e3181c0c3cb
   PubMed Web of Science ®Google Scholar
• Morris EC, Stauss HJ. Optimizing T cell receptor gene therapy for hematologic malignancies. Blood 2016; 127(26):3305-11; PMID:27207802; http://dx.doi.org/10.1182/blood-2015-11-629071.
   PubMed Web of Science ®Google Scholar
• Linnemann C, Heemskerk B, Kvistborg P, Kluin RJ, Bolotin DA, Chen X, Bresser K, Nieuwland M, Schotte R, Michels S, et al. High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med 2013; 19:1534-41; PMID:24121928; http://dx.doi.org/10.1038/nm.3359
   PubMed Web of Science ®Google Scholar
• Lass-Florl C, Roilides E, Loffler J, Wilflingseder D, Romani L. Minireview: host defence in invasive aspergillosis. Mycoses 2013; 56:403-13; PMID:23406508; http://dx.doi.org/10.1111/myc.12052
   PubMed Web of Science ®Google Scholar
• Camargo JF, Husain S. Immune correlates of protection in human invasive aspergillosis. Clin Infect Dis 2014; 59:569-77; PMID:24803380; http://dx.doi.org/10.1093/cid/ciu337
   PubMed Web of Science ®Google Scholar
• Ferwerda B, Ferwerda G, Plantinga TS, Willment JA, van Spriel AB, Venselaar H, Elbers CC, Johnson MD, Cambi A, Huysamen C, et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2009; 361:1760-7; PMID:19864674; http://dx.doi.org/10.1056/NEJMoa0901053
   PubMed Web of Science ®Google Scholar
• Cunha C, Di Ianni M, Bozza S, Giovannini G, Zagarella S, Zelante T, D'Angelo C, Pierini A, Pitzurra L, Falzetti F, et al. Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. Blood 2010; 116:5394-402; PMID:20807886; http://dx.doi.org/10.1182/blood-2010-04-279307
   PubMed Web of Science ®Google Scholar
• Cenci E, Mencacci A, Bacci A, Bistoni F, Kurup VP, Romani L. T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol 2000; 165:381-8; PMID:10861075; http://dx.doi.org/10.4049/jimmunol.165.1.381
   PubMed Web of Science ®Google Scholar
• Ito JI, Lyons JM. Vaccination of corticosteroid immunosuppressed mice against invasive pulmonary aspergillosis. J Infect Dis 2002; 186:869-71; PMID:12198627; http://dx.doi.org/10.1086/342509
   PubMed Web of Science ®Google Scholar
• Ito JI, Lyons JM, Hong TB, Tamae D, Liu YK, Wilczynski SP, Kalkum M. Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis. Infect Immun 2006; 74:5075-84; PMID:16926399; http://dx.doi.org/10.1128/IAI.00815-06
   PubMed Web of Science ®Google Scholar
• Diaz-Arevalo D, Bagramyan K, Hong TB, Ito JI, Kalkum M. CD4+ T cells mediate the protective effect of the recombinant Asp f3-based anti-aspergillosis vaccine. Infect Immun 2011; 79:2257-66; PMID:21422177; http://dx.doi.org/10.1128/IAI.01311-10
   PubMed Web of Science ®Google Scholar
• Bozza S, Gaziano R, Lipford GB, Montagnoli C, Bacci A, Di Francesco P, Kurup VP, Wagner H, Romani L. Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. Microbes Infect 2002; 4:1281-90; PMID:12443892; http://dx.doi.org/10.1016/S1286-4579(02)00007-2
   PubMed Web of Science ®Google Scholar
• Bozza S, Clavaud C, Giovannini G, Fontaine T, Beauvais A, Sarfati J, D'Angelo C, Perruccio K, Bonifazi P, Zagarella S, et al. Immune sensing of Aspergillus fumigatus proteins, glycolipids, and polysaccharides and the impact on Th immunity and vaccination. J Immunol 2009; 183:2407-14; PMID:19625642; http://dx.doi.org/10.4049/jimmunol.0900961
   PubMed Web of Science ®Google Scholar
• Khanna N, Stuehler C, Conrad B, Lurati S, Krappmann S, Einsele H, Berges C, Topp MS. Generation of a multipathogen-specific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154. Blood 2011; 118:1121-31; PMID:21642594; http://dx.doi.org/10.1182/blood-2010-12-322610
   PubMed Web of Science ®Google Scholar
• Chaudhary N, Staab JF, Marr KA. Healthy human T-Cell Responses to Aspergillus fumigatus antigens. PloS One 2010; 5:e9036; PMID:20174463; http://dx.doi.org/10.1371/journal.pone.0009036
   PubMed Web of Science ®Google Scholar
• Hebart H, Bollinger C, Fisch P, Sarfati J, Meisner C, Baur M, Loeffler J, Monod M, Latgé JP, Einsele H. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood 2002; 100:4521-8; PMID:12393638; http://dx.doi.org/10.1182/blood-2002-01-0265
   PubMed Web of Science ®Google Scholar
• Ramadan G, Davies B, Kurup VP, Keever-Taylor CA. Generation of Th1 T cell responses directed to a HLA Class II restricted epitope from the Aspergillus f16 allergen. Clin Exp Immunol 2005; 139:257-67; PMID:15654824; http://dx.doi.org/10.1111/j.1365-2249.2005.02699.x
   PubMed Web of Science ®Google Scholar
• Jolink H, Meijssen IC, Hagedoorn RS, Arentshorst M, Drijfhout JW, Mulder A, Claas FH, van Dissel JT, Falkenburg JH, Heemskerk MH. Characterization of the T-cell-mediated immune response against the Aspergillus fumigatus proteins Crf1 and catalase 1 in healthy individuals. J Infect Dis 2013; 208:847-56; PMID:23698813; http://dx.doi.org/10.1093/infdis/jit237
   PubMed Web of Science ®Google Scholar
• Stuehler C, Nowakowska J, Bernardini C, Topp MS, Battegay M, Passweg J, Khanna N. Multispecific Aspergillus T cells selected by CD137 or CD154 induce protective immune responses against the most relevant mold infections. J Infect Dis 2015; 211:1251-61; PMID:25367298
   PubMed Web of Science ®Google Scholar
• Jolink H, Hagedoorn RS, Lagendijk EL, Drijfhout JW, van Dissel JT, Falkenburg JH, Heemskerk MH. Induction of A. fumigatus-specific CD4-positive T cells in patients recovering from invasive aspergillosis. Haematologica 2014; 99:1255-63; PMID:24747947; http://dx.doi.org/10.3324/haematol.2013.098830
   PubMed Web of Science ®Google Scholar
• Potenza L, Vallerini D, Barozzi P, Riva G, Forghieri F, Beauvais A, Beau R, Candoni A, Maertens J, Rossi G, et al. Characterization of specific immune responses to different Aspergillus antigens during the course of invasive Aspergillosis in hematologic patients. PloS One 2013; 8:e74326; PMID:24023936; http://dx.doi.org/10.1371/journal.pone.0074326
   PubMed Web of Science ®Google Scholar
• Tramsen L, Koehl U, Tonn T, Latge JP, Schuster FR, Borkhardt A, Uharek L, Quaritsch R, Beck O, Seifried E, et al. Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapy. Bone Marrow Transplant 2009; 43:13-9; PMID:18762764; http://dx.doi.org/10.1038/bmt.2008.271
   PubMed Web of Science ®Google Scholar
• Tramsen L, Schmidt S, Boenig H, Latge JP, Lass-Florl C, Roeger F, Seifried E, Klingebiel T, Lehrnbecher T. Clinical-scale generation of multi-specific anti-fungal T cells targeting Candida, Aspergillus and mucormycetes. Cytotherapy 2013; 15:344-51; PMID:23579059; http://dx.doi.org/10.1016/j.jcyt.2012.11.014
   PubMed Web of Science ®Google Scholar
• Stuehler C, Khanna N, Bozza S, Zelante T, Moretti S, Kruhm M, Lurati S, Conrad B, Worschech E, Stevanović S, et al. Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans. Blood 2011; 117:5881-91; PMID:21441461; http://dx.doi.org/10.1182/blood-2010-12-325084
   PubMed Web of Science ®Google Scholar
• Perruccio K, Tosti A, Burchielli E, Topini F, Ruggeri L, Carotti A, Capanni M, Urbani E, Mancusi A, Aversa F, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005; 106:4397-406; PMID:16123217; http://dx.doi.org/10.1182/blood-2005-05-1775
   PubMed Web of Science ®Google Scholar
• Kumaresan PR, Manuri PR, Albert ND, Maiti S, Singh H, Mi T, Roszik J, Rabinovich B, Olivares S, Krishnamurthy J, et al. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci U S A 2014; 111:10660-5; PMID:25002471; http://dx.doi.org/10.1073/pnas.1312789111
   PubMed Web of Science ®Google Scholar
• Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, Maiti S, Manuri P, Senyukov V, Jena B, et al. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PloS One 2013; 8:e64138; PMID:23741305; http://dx.doi.org/10.1371/journal.pone.0064138
   PubMed Web of Science ®Google Scholar
• Curran KJ, Pegram HJ, Brentjens RJ. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med 2012; 14:405-15; PMID:22262649; http://dx.doi.org/10.1002/jgm.2604
   PubMed Web of Science ®Google Scholar
• Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014; 123:2625-35; PMID:24578504; http://dx.doi.org/10.1182/blood-2013-11-492231
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371:1507-17; PMID:25317870; http://dx.doi.org/10.1056/NEJMoa1407222
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 2016; 126:2123-38; PMID:27111235; http://dx.doi.org/10.1172/JCI85309
   PubMed Web of Science ®Google Scholar
• Cunha C, Carvalho A, Esposito A, Bistoni F, Romani L. DAMP signaling in fungal infections and diseases. Front Immunol 2012; 3:286; PMID:22973279; http://dx.doi.org/10.3389/fimmu.2012.00286
   PubMed Web of Science ®Google Scholar
• Marin V, Cribioli E, Philip B, Tettamanti S, Pizzitola I, Biondi A, Biagi E, Pule M. Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. Hum Gene Ther Methods 2012; 23:376-86; PMID:23186165; http://dx.doi.org/10.1089/hgtb.2012.050
   PubMed Web of Science ®Google Scholar
• Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010; 116:1035-44; PMID:20439624; http://dx.doi.org/10.1182/blood-2010-01-043737
   PubMed Web of Science ®Google Scholar
• de Witte MA, Kierkels GJ, Straetemans T, Britten CM, Kuball J. Orchestrating an immune response against cancer with engineered immune cells expressing alphabetaTCRs, CARs, and innate immune receptors: an immunological and regulatory challenge. Cancer Immunol Immunother 2015; 64:893-902; PMID:25990073; http://dx.doi.org/10.1007/s00262-015-1710-8
   PubMed Web of Science ®Google Scholar
• Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunocompromised hosts: immunopharmacology of modern antifungals. Clin Infect Dis 2008; 47:226-35; PMID:18540822; http://dx.doi.org/10.1086/589290
   PubMed Web of Science ®Google Scholar
• Lamaris GA, Lewis RE, Chamilos G, May GS, Safdar A, Walsh TJ, Raad II, Kontoyiannis DP. Caspofungin-mediated β-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis 2008; 198:186-92; PMID:18500936; http://dx.doi.org/10.1086/589305
   PubMed Web of Science ®Google Scholar
• Cenci E, Mencacci A, Del Sero G, Bistoni F, Romani L. Induction of protective Th1 responses to Candida albicans by antifungal therapy alone or in combination with an interleukin-4 antagonist. J Infect Dis 1997; 176:217-26; PMID:9207370; http://dx.doi.org/10.1086/514027
   PubMed Web of Science ®Google Scholar